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Cdc42 is activated by RANKL or M-CSF. Cytokine- and serum-starved 
WT pre-osteoclasts were exposed to RANKL (100 ng/ml) or M-CSF 
(50 ng/ml) over time. Cdc42-GTP was assessed by pulldown assay. 
Total Cdc42 and β-actin served as loading controls.
Figure 2
Cdc42 modulates multiple RANKL and M-CSF signaling pathways. (A and B) Cytokine- and serum-starved BMMs were exposed to M-CSF 
(50 ng/ml) over time. Total and phosphorylated signaling molecules were detected by Western blots. β-Actin served as loading control. (C and 
D) Cytokine- and serum-starved BMMs were exposed to RANKL (100 ng/ml) over time. Total and phosphorylated signaling molecules were 
detected by Western blots. β-Actin served as loading control.
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Cdc42 regulates proliferation and survival of osteoclast lineage cells. (A) BrdU incorporation of WT, Cdc42–/–, and Cdc42–/– rescued with WT 
Cdc42 BMMs exposed to M-CSF (50 ng/ml) for 12 hours. (B) BrdU incorporation by WT, Cdc42Gap–/–, Cdc42Gap–/– transduced with WT, or 
GAP-deficient mutant Cdc42GAPR305A BMMs exposed to M-CSF (50 ng/ml) for 12 hours. (C and D) Immunoblots of D-type cyclins and phos-
phorylation of retinoblastoma protein (Rb) in response to M-CSF. β-Actin served as a loading control. (E) TRAP staining of WT and Cdc42ΔOC/ΔOC 
osteoclasts. Apoptotic osteoclasts are indicated with asterisks. Original magnification, ×200. (F and G) ELISA-determined osteoclast apoptosis. 
(H and I) Immunoblots of cleaved caspase-3, -9, and -8 and Bim in mature WT, Cdc42ΔOC/ΔOC, and Cdc42Gap–/– osteoclasts. 5′ represents mature 
osteoclasts deprived of cytokines and serum for 3 hours prior to assay. β-Actin served as a loading control. Data are presented as mean ± SD 
(**P < 0.01; ***P < 0.001).
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Figure 4
Cdc42 regulates osteoclast differentiation in 
vitro. (A) TRAP staining of osteoclasts gen-
erated from WT and Cdc42–/– BMMs pro-
duced by transducing Cdc42fl/fl BMMs with 
retrovirus expressing Cre recombinase, and 
Cdc42–/– BMMs rescued with WT Cdc42. 
Original magnification, ×200. (B) Quantifica-
tion of the number of TRAP+ multinucleated 
osteoclasts (MNCs) shown in A. (C) TRAP 
staining of osteoclasts generated from WT or 
Cdc42Gap–/– BMMs or Cdc42Gap–/– BMMs 
transduced with either WT or the GAP-defi-
cient mutant, Cdc42GapR305A. Original mag-
nification, ×40. (D) Quantification of results 
from C. (E) Osteoclast (OC) differentiation 
markers assessed by RT-PCR. Numbers 
represent densitometrically determined ratios 
relative to GAPDH. (F) Osteoclast differen-
tiation markers assessed by immunoblot. 
Numbers represent densitometrically deter-
mined ratios relative to β-actin. (G) Induction 
of NFATc1 protein during osteoclast differ-
entiation of WT and Cdc42–/– BMMs. β-Actin 
served as loading control. (H) MITF phos-
phorylation with time of exposure to RANKL. 
β-Actin served as loading control. Data shown 
in B and D are presented as mean ± SD 
(**P < 0.01; ***P < 0.001).
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Cdc42 promotes bone resorption in vitro. (A, C, and D) Bone resorption pits labeled by lectin (brown reaction product). Original magnification, 
×200. (B and E) Culture medium CTx-1 determined by ELISA. Data are presented as mean ± SD (*P < 0.05).
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(24), was  enhanced  in Cdc42Gap–/–  cells  (Figure 4, G  and H). 
Thus, Cdc42 promotes osteoclast differentiation.
Figure 6
Cdc42 regulates actin ring kinetics. (A and D) F-actin staining in osteoclasts generated on bone slices demonstrated actin rings in all panels. 
(B and E) Quantification of the number of actin ring–containing osteoclasts illustrated in A and D, respectively. (C) Actin ring re-formation assay 
in mature WT and Cdc42ΔOC/ΔOC osteoclasts. Mature osteoclasts, cultured on bone, were washed with cold cytokine-free medium, followed by 
incubation at 37°C for 30 minutes. RANKL (100 ng/ml) was then added for the indicated time. Bone slices were fixed, and F-actin was stained 
with Alexa Fluor 488–phalloidin. The number of total osteoclasts and those with actin rings were counted. Data are presented as mean ± SD 
(*P < 0.05; **P < 0.01; ***P < 0.001).
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Par-3/Par-6/aPKCs complex mediates Cdc42-regulated osteoclast polarization. (A) RANKL stimulates threonine and tyrosine phosphorylation 
of aPKCs in mature osteoclasts. Mature osteoclasts, generated by 5 days’ exposure of WT BMMs to RANKL and M-CSF, were serum- and 
cytokine-starved and then treated with RANKL over time. Left: Lysates were immunoblotted for threonine-phosphorylated and total aPKC. Right: 
Lysates were immunoprecipitated for total phosphotyrosine (p-Y) using mAb 4G10 or aPKC. Immunoprecipitates were immunoblotted for aPKC. 
(B) Immunoprecipitation of endogenous aPKCs in osteoclasts transduced with empty vector (pMX), HA-tagged dominant-negative (Cdc42-17N), 
or HA-tagged constitutively active (Cdc42-12V) retroviruses. TCL: total cell lysates. (C) Co-immunoprecipitation of HA-tagged Par-6 with aPKCs 
and LGL in osteoclasts. (D) Co-immunoprecipitation of endogenous Par-3 in osteoclasts transduced with pMX, N-terminal–FLAG-tagged PKC-λ 
(N-FLAG-aPKC), or C-terminal–FLAG–tagged PKC-λ (C-FLAG-aPKC). (E) Co-immunoprecipitation of endogenous Par-3 in osteoclasts trans-
duced with N-terminal HA-tagged par-6 (N-HA par-6) or C-terminal HA-tagged par-6 (C-HA par-6). (F) Selective inhibition of PKC isoforms in 
mature osteoclasts, cultured on bone slices, by 1 hour exposure to cell-permeable pseudo substrate (PS) peptide inhibitors of PKC-α, PKC-θ, 
PKC-ε, PKC-ζ, and Go 6976. (G) Osteoclasts were incubated with PKC-ζ inhibitor or carrier for 1 hour followed by washing and cultured for 
1 or 3 hours. Cells were stained to visualize actin rings. Hoechst stain visualizes nuclei. Original magnification, ×200. (H) Quantification of the 
percentage of osteoclasts exhibiting actin rings illustrated in F (***P < 0.001).
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Cdc42 is essential for osteoclastic bone resorption in vivo and its abla-







trabecular  number  and  thickness,  and  these  changes were 
accompanied by decreased  trabecular  separation  (Figure 8, 
Figure 8
Increased bone mass in Cdc42ΔOC/ΔOC mice due to suppressed resorption. 
(A) WT and Cdc42ΔOC/ΔOC mice. (B) Radiographs of femurs from 8-week- 
old CtsKCre/+Cdc42+/+ (WT) and CtsKCre/+Cdc42fl/fl (Cdc42ΔOC/ΔOC) 
male mice. (C) μCT images of distal femoral metaphysis of WT and 
Cdc42ΔOC/ΔOC mice. (D) TRAP-stained histological sections of proximal 
tibia of WT and Cdc42ΔOC/ΔOC mice (n = 10). Original magnification, 
×40. (E) μCT determination of BV/TV, trabecular number (Tb. No), tra-
becular thickness (Tb. Th), and trabecular separation (Tb. Sp) of distal 
femoral metaphysis. (F) Serum CTx-1 of WT and Cdc42ΔOC/ΔOC mice. 
(G) μCT determination of BV/TV of distal femoral metaphysis from 
10 sham-operated (sham) or ovariectomized 12-week-old WT and 
Cdc42ΔOC/ΔOC mice 4 weeks after surgery. (H) WT and Cdc42ΔOC/ΔOC 
tibiae were stained for TRAP activity, and the percentage of bone sur-
face in juxtaposition to osteoclasts was histomorphometrically deter-
mined. (I) Double staining of TUNEL and TRAP in histological sections 
of proximal tibia. TRAP+ multinucleated osteoclasts are indicated by 
arrows, and those staining for both TRAP and TUNEL are indicated by 
arrowheads. Original magnification, ×400. (J) Percentage of TUNEL-
positive osteoclasts shown in I (*P < 0.05; **P < 0.01; ***P < 0.001).
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Decreased bone mass in Cdc42Gap–/– chimeric mice due to enhanced bone resorption. (A) BMD of lumbar vertebrae measured by DEXA in WT 
and Cdc42Gap–/– chimeric mice 2 months and 4 months after marrow transplantation. (B) TRAP-stained histological sections of proximal tibia 
of WT and Cdc42Gap–/– chimeric mice 4 months after transplantation (n = 10). Original magnification, ×40. (C) BV/TV and osteoclast perimeter 
per bone perimeter (OC Pm/B Pm) calculated from B. (D) Serum TRAP5b and CTx-1 in WT and Cdc42Gap–/– chimeric mice 4 months after 
transplantation, as measured by ELISA. Data are presented as mean ± SD (*P < 0.05; **P < 0.01; ***P < 0.001).
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Model of Cdc42-mediated regulation of osteoclast lineage cell prolif-
eration, apoptosis, differentiation, and function.
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